Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) is set to participate in key investor conferences, including the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, and the Morgan Stanley 20th Annual Global Healthcare Conference, which will feature a fireside chat on September 14, 2022, at 10:00 a.m. ET. The Morgan Stanley chat will be available live via the Fulcrum Investor Relations website, with a recording accessible for 30 days afterward. Fulcrum focuses on rare genetic diseases and has two lead programs in development: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:

• H.C. Wainwright 24th Annual Global Investment Conference
  Tuesday, September 13, 2022

• Morgan Stanley 20th Annual Global Healthcare Conference
  Wednesday, September 14, 2022 at 10:00 a.m. ET (Fireside Chat)

A live audio webcast of the Morgan Stanley fireside chat will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, please visit www.fulcrumtx.com.

Contacts:

Investors
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

Media
Dee Smith
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
dsmith@fulcrumtx.com
202-746-1324

FAQ

What conferences is Fulcrum Therapeutics participating in September 2022?

Fulcrum Therapeutics will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022.

When is Fulcrum's fireside chat at the Morgan Stanley conference?

The fireside chat at the Morgan Stanley conference is scheduled for September 14, 2022, at 10:00 a.m. ET.

Where can I watch the live audio webcast of Fulcrum's fireside chat?

The live audio webcast of the fireside chat can be accessed through the Investor Relations section of Fulcrum's website.

What are the lead programs of Fulcrum Therapeutics?

Fulcrum's lead programs in development include losmapimod for treating facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.